{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:01:46Z","timestamp":1770483706665,"version":"3.49.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1380,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1365-2230.2011.04219.x","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T13:44:59Z","timestamp":1321883099000},"page":"146-148","source":"Crossref","is-referenced-by-count":12,"title":["Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum"],"prefix":"10.1093","volume":"37","author":[{"given":"M. S.","family":"Shareef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. R.","family":"Munro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. G.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Highet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,11,21]]},"reference":[{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000106584","article-title":"Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review","volume":"215","author":"Juillerat","year":"2007","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archderm.1983.01650300022009","article-title":"Pyoderma gangrenosum and monoclonal gammopathy","volume":"119","author":"Powell","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428190701361224","article-title":"IgG multiple myeloma presented with ulcerative pyoderma gangrenosum","volume":"48","author":"Verrou","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1007\/s10620-006-9165-6","article-title":"Review article: multiple myeloma and inflammatory bowel disease","volume":"52","author":"Reynolds","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10620-007-9932-z","article-title":"Association of multiple myeloma and inflammatory bowel diseases","volume":"53","author":"Liu","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009740701286904","article-title":"Monoclonal gammopathy of undetermined significance and anti-TNF-alpha treatment","volume":"36","author":"Smale","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1111\/j.1365-2230.2011.04219.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(02)00082-6","article-title":"Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2011.04219.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2230.2011.04219.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:10:04Z","timestamp":1676383804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/37\/2\/146\/6622759"}},"subtitle":["Progression of IgA gammopathy to myeloma following infliximab treatment for PG"],"short-title":[],"issued":{"date-parts":[[2011,11,21]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04219.x","relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,21]]}}}